1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Australian HTA Review: Sponsors Attack Use Of Cheap Comparators, Want More Streamlined Procedures

 
• By Ian Schofield

Shortcomings in the health technology assessment system are discouraging some companies from investing in Australia, according to responses to a recent consultation on the ongoing HTA review.

Health care concept for economic cost-effectiveness analysis
Australia is planning to overhaul its system for assessing the value of new medicines • Source: Shutterstock

Australians are missing out on new medicines because of a health technology assessment (HTA) policy that seeks to link the cost of new drugs to the lowest cost product, including generics, and not to the price of the medicine it will replace, says Gilead Sciences.

A “more balanced approach to uncertainty” is needed and HTA processes should be “conducted independently from government choices on health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Market Access

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Respiratory Treatments Hit Hardest By HTA Terminations In England

 
• By Leela Barham

Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.

New Pricing Agreements And Greater Transparency: What A US MFN Policy Could Mean For France

 
• By Francesca Bruce

A potential MFN drug pricing policy in the US could also lead to a greater push for collaborative action in the EU, such as joint procurement among the member states, says one European industry expert.